Nakayama Lion’s Mane (Hericium erinaceus 'Nakayama')
Nakayama Lion's Mane (Hericium erinaceus 'Nakayama') is a cultivated strain of Lion's Mane mushroom containing hericenones and erinacines, bioactive compounds that stimulate nerve growth factor (NGF) synthesis. Its primary mechanisms include NGF-dependent neuroprotection and suppression of neuroinflammatory signaling via iNOS and p38 MAPK pathway inhibition.
Origin & History
Hericium erinaceus 'Nakayama' is a specific cultivar variant of lion's mane mushroom, a medicinal fungus that grows on hardwood trees in Asia, North America, and Europe. This mushroom is typically processed into water or alcohol extracts, or dried mycelium powder, with active compounds like erinacine A concentrated in standardized formulations.
Historical & Cultural Context
The research dossier notes a significant gap in documentation of traditional medicine use for H. erinaceus, with no specific information provided on historical systems (Chinese, Japanese, etc.) or traditional indications. This limits the ability to provide comprehensive traditional medicine context for this ingredient.
Health Benefits
• Cognitive improvement in mild cognitive impairment: Clinical trial showed significant improvements on MMSE scores, though systematic review noted effects didn't always separate from placebo • Neuroprotection through anti-inflammatory pathways: Preclinical evidence shows inhibition of iNOS/p38 MAPK/CHOP signaling, reducing brain tissue damage • Enhanced neurogenesis and BDNF production: Animal studies demonstrate increased hippocampal neurogenesis and brain-derived neurotrophic factor expression • Mood support through neurotransmitter modulation: Animal models show increased dopamine and serotonin levels in depression studies • Gut microbiota support: Preclinical evidence indicates increased microbiota diversity and SCFA-producing bacteria abundance
How It Works
Nakayama Lion's Mane delivers hericenones (from fruiting body) and erinacines (from mycelium), which cross the blood-brain barrier and upregulate nerve growth factor (NGF) biosynthesis, promoting neuronal survival and differentiation. It also suppresses neuroinflammation by inhibiting inducible nitric oxide synthase (iNOS) and blocking phosphorylation of p38 mitogen-activated protein kinase (MAPK), reducing downstream pro-inflammatory cytokine production. These dual mechanisms—neurotrophic support and anti-inflammatory modulation—are thought to underlie its observed cognitive benefits.
Scientific Research
Clinical evidence remains limited with only five randomized controlled trials identified in a 2024 review (PMID: 40959699). A study on mild cognitive impairment demonstrated improvements on MMSE scores, while an unpublished trial in 36 Alzheimer's patients using erinacine-enriched mycelia showed promising results. A 2023 review emphasized that despite promising preclinical investigations, only a limited number of clinical trials have been conducted in neurological conditions.
Clinical Summary
A double-blind, placebo-controlled clinical trial using Hericium erinaceus (relevant to the Nakayama strain lineage) in adults with mild cognitive impairment demonstrated significant improvements in Mini-Mental State Examination (MMSE) scores over 16 weeks of supplementation at approximately 3g/day of dried mushroom powder. However, a subsequent systematic review noted that effect sizes were modest and did not consistently separate from placebo across all cognitive sub-domains, limiting confidence in the findings. Most supporting evidence remains preclinical, derived from in vitro and rodent models showing NGF upregulation and reduced neuroinflammatory markers. Overall, the clinical evidence is promising but preliminary, and larger, strain-specific randomized controlled trials are needed.
Nutritional Profile
{"macronutrients": {"protein": "2.4 g per 100 g", "fiber": "2.8 g per 100 g", "carbohydrates": "6.8 g per 100 g", "fats": "0.3 g per 100 g"}, "micronutrients": {"vitamins": {"vitamin D": "2.1 \u00b5g per 100 g", "vitamin B2 (Riboflavin)": "0.35 mg per 100 g"}, "minerals": {"potassium": "300 mg per 100 g", "phosphorus": "120 mg per 100 g", "magnesium": "15 mg per 100 g"}}, "bioactive_compounds": {"erinacines": "0.5 mg per 100 g", "hericenones": "0.3 mg per 100 g", "polysaccharides": "4.0 g per 100 g"}, "bioavailability_notes": "The bioavailability of erinacines and hericenones may be enhanced through cooking, while polysaccharides are generally well-absorbed in their natural form."}
Preparation & Dosage
Clinically studied dosages include: erinacine A-enriched mycelium at 10.76-21.52 mg/day (mouse models for neurotoxicity), 200-400 mg/kg body weight (animal depression models). Human studies have used durations from 4 to 49 weeks, though specific human dosing protocols are not consistently reported. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
BDNF-supporting nutrients, Omega-3 fatty acids, B-complex vitamins, Ginkgo biloba, Phosphatidylserine
Safety & Interactions
Hericium erinaceus, including the Nakayama strain, is generally well tolerated in human trials, with the most commonly reported adverse effects being mild gastrointestinal discomfort and, rarely, skin rashes or itching possibly linked to NGF sensitization. Individuals with mushroom allergies or known hypersensitivity to Hericium species should avoid use, and at least one case report documents an allergic respiratory reaction. Theoretical interactions exist with anticoagulant or antiplatelet drugs such as warfarin, as some Lion's Mane extracts may mildly inhibit platelet aggregation, warranting caution in patients on blood thinners. Safety data for use during pregnancy or lactation is insufficient, and use in these populations is not currently recommended.